Suppr超能文献

肝内采样阐明抗病毒临床药理学。

Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology.

机构信息

Center for Human Experimental Therapeutics, University of Rochester, Rochester, NY, USA.

AIDS Clinical Trials Group Pharmacology Specialty Laboratory, New York State Center of Excellence in Bioinformatics and Life Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA.

出版信息

Clin Pharmacol Drug Dev. 2017 Mar;6(2):169-175. doi: 10.1002/cpdd.311.

Abstract

Although the importance of the liver in clinical pharmacology is widely recognized, little is known in humans concerning its function in vivo at the hepatocyte level and how pharmacological functions are altered in the setting of advanced liver disease. Several recent proof-of-principle studies with first-generation DAAs have demonstrated the feasibility of serial liver sampling for pharmacological studies. These studies have begun to describe the liver-to-plasma concentration ratio and how this ratio is altered in the setting of advanced liver disease. These data are particularly relevant to individuals with substance-use disorders because many have advanced liver disease as a consequence of long-standing viral hepatitis infection or continued use of hepatotoxins such as alcohol. Future research should attempt to develop standardized and reproducible methods to assess liver drug concentration, complex drug interactions, and pharmacogenomics in humans to permit elucidation of the clinical pharmacology within the liver.

摘要

尽管肝脏在临床药理学中的重要性已被广泛认识,但人类对其在肝细胞水平上的体内功能知之甚少,也不清楚在晚期肝病中药物作用是如何改变的。最近几项使用第一代 DAAs 的原理验证研究证明了对肝脏进行多次采样以进行药理学研究的可行性。这些研究开始描述肝脏与血浆的浓度比值,以及在晚期肝病中该比值如何改变。这些数据对于有物质使用障碍的个体尤其重要,因为许多人由于长期的病毒性肝炎感染或持续使用酒精等肝毒素而患有晚期肝病。未来的研究应尝试开发标准化和可重复的方法来评估人类的肝脏药物浓度、复杂的药物相互作用和药物基因组学,以阐明肝脏内的临床药理学。

相似文献

1
Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology.
Clin Pharmacol Drug Dev. 2017 Mar;6(2):169-175. doi: 10.1002/cpdd.311.
2
Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus.
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02587-17. Print 2018 May.
3
Drug-Drug Interactions and Diagnostics for Drug Users With HIV and HIV/HCV Coinfections: Introduction.
Clin Pharmacol Drug Dev. 2017 Mar;6(2):108-117. doi: 10.1002/cpdd.316.
4
Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.
Clin Liver Dis. 2003 Feb;7(1):261-87. doi: 10.1016/s1089-3261(02)00078-8.
5
NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements. 2002;19(3):1-46.
7
Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C.
Gastroenterology. 2012 Sep;143(3):777-786.e6. doi: 10.1053/j.gastro.2012.05.044. Epub 2012 Jun 4.
8
Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C.
Expert Opin Drug Metab Toxicol. 2015 Jul;11(7):1157-65. doi: 10.1517/17425255.2015.1049532. Epub 2015 May 25.
9
Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy.
World J Gastroenterol. 2018 Dec 21;24(47):5297-5311. doi: 10.3748/wjg.v24.i47.5297.

引用本文的文献

1
Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.
PLoS One. 2018 Oct 16;13(10):e0204974. doi: 10.1371/journal.pone.0204974. eCollection 2018.

本文引用的文献

2
Elbasvir/Grazoprevir: First Global Approval.
Drugs. 2016 Apr;76(5):617-24. doi: 10.1007/s40265-016-0558-3.
4
Pharmacokinetic drug interactions in liver disease: An update.
World J Gastroenterol. 2016 Jan 21;22(3):1260-78. doi: 10.3748/wjg.v22.i3.1260.
5
Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
Antimicrob Agents Chemother. 2015 Nov 23;60(2):855-61. doi: 10.1128/AAC.01913-15. Print 2016 Feb.
9
Liver-to-plasma vaniprevir (MK-7009) concentration ratios in HCV-infected patients.
Antivir Ther. 2015;20(8):843-8. doi: 10.3851/IMP2958. Epub 2015 Apr 7.
10
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics.
Int J Antimicrob Agents. 2015 Jun;45(6):657-61. doi: 10.1016/j.ijantimicag.2015.01.019. Epub 2015 Mar 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验